BIA Separations d.o.o.. (3/5/18). "Press Release: BIA Separations and Nuvonis Technologies Partner to Support Vaccine and Gene Therapy Production". Ajdovšcina & Vienna.

	Organisation	BIA Separations d.o.o.
	Group	Sartorius (Group)
	Organisation 2	Nuvonis Technologies GmbH
	Product	CIM® column (Convective Interaction Media monolithic chromatographic column)
	Index term	BIA Separations–Nuvonis: vaccine + gene therapy production technology, 201710– collab co-marketing of cell lines + purification technologies
	Person	Štrancar, Aleš (BIA Separations 201309 CEO + Chief Business Development Officer)
	Person 2	Poandl, Josef (Nuvonis Technologies 201803 Chairman)

Agreement combines strengths in upstream and downstream process development

BIA Separations, a leading biochromatography development and manufacturing company, and Nuvonis Technologies (Nuvonis), a biotech company providing innovative production cell banks, today announced they have signed a partnership agreement. The companies will offer solutions to meet the growing demand for vaccine and gene therapy production, and tackle the technical challenges associated with managing the upstream/downstream process interface.

The partnership agreement will provide customers with an offering that combines Nuvonis’ unique Vero cell bank with BIA Separation’s CIM monolithic column purification products, along with both companies’ deep understanding for upstream and downstream process development. The companies will work with customers to create targeted solutions to improve manufacturing process execution, for the development of manufacturing procedures for gene therapy, oncolytic vaccines, exosomes and similar biomolecules. The integrated offering will significantly reduce costs, by providing a single source of expertise and reducing redundancy in process development.

Aleš Štrancar, CEO of BIA Separations, commented: “The interface between upstream and downstream bioprocessing is one of the most challenging technical areas remaining in the field, and where most production problems arise. I look forward to seeing our teams working together to bring effective solutions to clients of any size – small, medium and large.”

Josef Poandl, Chairman of Nuvonis Technologies’ board, said: “Choosing a well characterized Vero cell substrate and designing a simple high yield purification process is an important strategic element to most vaccine and gene therapy companies. By working together with BIA Separations, we will be able to offer unique solutions to improve production.”

ENDS

Notes to Editors

Media contact
Sarah Jeffery
Zyme Communications
E: sarah.jeffery@zymecommunications.com
T: +44 (0)7771 730 919

At BIA Separations
Jana Krapež Trošt
Head of Marketing
E: marketing@monoliths.com
T: +386 (0)59 699 505

At Nuvonis Technologies
Joachim Seipelt
Head of Business Development
E: j.seipelt@nuvonis.com
T: +43 699 12350457

About BIA Separations
www.biaseparations.com

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns for production, purification, and analytics of large biomolecules. The company has research and production facilities in Slovenia, with sales offices and distributors throughout the world.

BIA Separations mission is to develop and produce CIM® monolithic columns of highest quality and provide superior research and method development services for purification and analytics of biomolecules. In addition the company aims to provide unique in-process control tools to better understand and control the bioprocesses.

About Nuvonis Technologies
www.nuvonis.com

NUVONIS is a biotech company providing innovative production cell banks as well as technical support for production processes and vaccine strain improvement.

The company provides GMP Master and Working Cell Banks for vaccine development and production. Fully characterized, including tumorigenicity, its cell banks can be used as growth substrate for a variety of viruses applied in modern vaccine development.

The NUVONIS team is highly experienced in the development and optimization of up- and downstream vaccine production processes, offering a proprietary and efficient virus purification process for the generation of high purity vaccine bulk drug substance meeting regulatory requirements in terms of host cell DNA and protein limits.

Record changed: 2023-06-05